21 results
Keyword Alemtuzumab Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Lemtrada (updated)
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013, Revision: 7, AuthorisedLemtrada INN-alemtuzumab 30 Churchill Place … for the public Lemtrada alemtuzumab This is a summary of the … contains the active substance alemtuzumab. How is Lemtrada used … -
List item
Human medicine European public assessment report (EPAR): MabCampath
alemtuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 06/07/2001, Revision: 14, Withdrawnstatement on MabCampath (alemtuzumab): Withdrawal of the marketing … Public statement MabCampath (alemtuzumab) Withdrawal of the marketing … medicinal product MabCampath (alemtuzumab) for the treatment of patients … -
List item
Human medicine European public assessment report (EPAR): Arzerra
ofatumumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 19/04/2010, Revision: 16, Authorisedfludarabine and a medicine called alemtuzumab; • in patients whose … to both fludarabine and alemtuzumab, and in 112, treatment with … had not been treated with alemtuzumab because this medicine was … -
List item
Human medicine European public assessment report (EPAR): Gilenya
fingolimod, Multiple Sclerosis
Date of authorisation: 17/03/2011, Additional monitoring, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Tysabri
natalizumab, Multiple Sclerosis
Date of authorisation: 27/06/2006, Additional monitoring, Revision: 27, Authorised -
List item
Human medicine European public assessment report (EPAR): Mavenclad
cladribine, Multiple Sclerosis
Date of authorisation: 22/08/2017, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Ocrevus (updated)
ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018, Additional monitoring, Revision: 3, Authorised -
List item
Human medicine European public assessment report (EPAR): Prevymis
letermovir, Cytomegalovirus Infections
Date of authorisation: 08/01/2018, Additional monitoring, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Imbruvica
ibrutinib, Lymphoma, Mantle-Cell Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014, Additional monitoring, Revision: 12, Authorised -
List item
Human medicine European public assessment report (EPAR): Folotyn
pralatrexate, Lymphoma, T-Cell
Date of refusal: 21/06/2012, Refuseddeoxycoformycin, denileukin diftitox, alemtuzumab, and lenalidomide. Published … -
List item
Human medicine European public assessment report (EPAR): Gazyvaro
obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 22/07/2014, Additional monitoring, Revision: 7, Authorisedas well as the comparators alemtuzumab and cetuximab. After 24 … -
List item
Human medicine European public assessment report (EPAR): Zessly
infliximab, Arthritis, Psoriatic Psoriasis Crohn Disease Arthritis, Rheumatoid Colitis, Ulcerative Spondylitis, Ankylosing
Date of authorisation: 18/05/2018, Additional monitoring, Biosimilar, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Torisel
temsirolimus, Carcinoma, Renal Cell Lymphoma, Mantle-Cell
Date of authorisation: 19/11/2007, Revision: 28, Authorised -
List item
Human medicine European public assessment report (EPAR): Zinbryta
daclizumab, Multiple Sclerosis
Date of authorisation: 01/07/2016, Additional monitoring, Revision: 8, Withdrawnevolving severe disease. Alemtuzumab is a monoclonal antibody … -
List item
Human medicine European public assessment report (EPAR): Erelzi
etanercept, Arthritis, Psoriatic Psoriasis Arthritis, Juvenile Rheumatoid Arthritis, Rheumatoid Spondylitis, Ankylosing
Date of authorisation: 23/06/2017, Additional monitoring, Biosimilar, Revision: 3, Authorised -
List item
Human medicine European public assessment report (EPAR): Istodax
romidepsin, Lymphoma, Non-Hodgkin
Date of refusal: 12/02/2013, Refused -
List item
Human medicine European public assessment report (EPAR): Venclyxto
venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016, Additional monitoring, Conditional approval, Revision: 7, AuthorisedMarketing authorization for alemtuzumab, which had been indicated … -
List item
Human medicine European public assessment report (EPAR): Zydelig
idelalisib, Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 18/09/2014, Additional monitoring, Revision: 14, Authorised -
List item
Human medicine European public assessment report (EPAR): Revolade
eltrombopag, Purpura, Thrombocytopenic, Idiopathic
Date of authorisation: 11/03/2010, Revision: 21, Authorised -
List item
Human medicine European public assessment report (EPAR): Nerventra
laquinimod, Multiple Sclerosis
Date of refusal: 19/08/2014, Refusednatalizumab (Tysabri) and Alemtuzumab (Lemtrada). Lemtrada was … -
List item
Human medicine European public assessment report (EPAR): Cosentyx
secukinumab, Arthritis, Psoriatic Psoriasis Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Additional monitoring, Revision: 11, Authorised